Abstract: The present invention provides a method of treating insulin-dependent diabetes mellitus in a subject, comprising administering to the subject a therapeutically effective amount of a Janus kinase inhibitor, or a pharmaceutically acceptable salt or ester thereof, or a therapeutically effective amount of intravenous immunoglobulin, or a therapeutically effective amount of a therapeutic agent that destroys B lymphocytes, or a combination thereof. The present invention also provides kits containing the same.

Abstract: An antimicrobial composition that includes: an antimicrobial component having at least one quaternary ammonium compound; a cationic polysaccharide; an organic acid; and a surfactant selected from cationic surfactants, amphoteric surfactants, nonionic surfactants and combinations thereof. This composition when applied to a surface provides robust long lasting disinfection.

Abstract: The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor alone or in combination with a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.

Abstract: Biocomposites comprising sulfated carboxymethyl cellulose and Azadirachta indica leaf extracts are provided. The sulfated carboxymethyl cellulose is made using an improved, environmentally friendly technique. Methods of using the biocomposites as anticoagulants are also provided.

Abstract: A sunscreen composition includes a silicone phase that includes at least one silicone film former, a blend of silicones that includes at least one of each of a low viscosity silicone fluid, a silicone co-emulsifier and a self-emulsifying silicone elastomer. The composition includes a UV filter system that includes one or more UV filters. The silicone film former and blend of silicones are present in quantities sufficient to provide an SPF that is boosted by at least 100% as compared to a composition that lacks silicone film former, and the cosmetic composition has a unique texture that provides low friction and high glide.

Abstract: The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:

Abstract: The invention relates to compositions of co-polymers having hydrophilic and biodegradable hydrophobic units or blocks, resulting in improved properties and functionalities suitable for biomedical applications as self-fitting tissue scaffolds or minimally invasive surgical implants.

Abstract: The invention relates to a process for producing food ingredients from Stevia rebaudiana plant and their use in food products, beverages and other consumables. Obtained compositions are useful as flavors, sweeteners, antioxidants, and other functional ingredients.

Abstract: Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a ?-cyclodextrin, e.g., a sulfo butyl ether ?-cyclodextrin, e.g., a ?-cyclodextrin, e.g., a sulfo butyl ether ?-cyclodextrin, e.g., CAPTISOL®; and methods of use in treating CNS disorders.

Abstract: The present disclosure relates to methods for screening test samples or substances that are capable of inducing or reducing nucleolar hypertrophy in cancer cells. The present disclosure further provides methods of contacting isolated cancer cells with a test sample or a substance that can induce nucleolar hypertrophy in a cancer cell. The present disclosure further provides methods for contacting an isolated cancer cell characterized by nucleolar hypertrophy with a test sample or substance that can reduce the nucleolar hypertrophy. One benefit to the method of screening disclosed herein can be the identification of test samples or substances capable of reducing nucleolar hypertrophy. Another benefit to the method of screening disclosed herein can be the identification of those combinations of test samples, substances, or combinations or series thereof, which are suitable or optimal for treating specific cancers in patients.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

Abstract: Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.

Abstract: According to the present disclosure, a bioadhesive formulation is provided. The bioadhesive formulation comprises a polycaprolactone dendrimer having a dendrimer core and a plurality of polycaprolactone chains extending from the dendrimer core, wherein at least one of the polycaprolactone chains has an end which is covalently attached with a diazirine, and wherein the diazirine converts to a carbene or a diazoalkyl when a stimulant is applied to the bioadhesive formulation. Methods of forming the bioadhesive formulation are also provided. The bioadhesive could be used in (i) the prevention of thrombosis from tissue fixation and/or (ii) the relief of discomfort and/or pain during and/or after surgery. Preferably, the bioadhesive formulation further comprises a hygroscopic additive, an antithrombotic agent, and/or an anaesthetic agent.

Abstract: An anhydrous dasatinib-containing preparation comprising an anhydrous dasatinib and a titanium oxide or colorant or antioxidant is provided. In one embodiment, the anhydrous dasatinib-containing preparation improves photostability upon storage. The weight ratio of the titanium oxide per the anhydrous dasatinib may be more than 0 and 2 or less, or the weight ratio of the colorant per the anhydrous dasatinib may be more than 0 and 1 or less, or the weight ratio of the antioxidant per the anhydrous dasatinib may be more than 0 and 0.5 or less.

Abstract: The purpose of the present invention is to provide a novel medicinal agent that is therapeutically more effective than conventional medicinal agents. The purpose is achieved by providing a fine nano-sized medicinal agent in which an active ingredient dispersed in a solvent has an average particle diameter of 1-20 nm.

Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

Abstract: The present invention relates to the treatment of leukemia, (e.g. acute myeloid leukemia, AML) using a triple combination of: arsenic trioxide; iron; and an artemisinin, such as artesunate.

Abstract: The present invention relates to pharmaceutical formulations comprising metolazone, a lipid, and an emulsifier that provide a lipid formulation of metolazone that can be administered intravenously to patients, thereby enhancing the therapeutic delivery and improving patient care for acute heart failure and resistant edmitious states.

Abstract: Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.

Abstract: The present invention thus relates to a solid composition, especially for coating keratin materials, more particularly for making up and/or caring for keratin materials such as the skin, in compact powder form, especially comprising a physiologically acceptable medium and containing at least:—an oily phase in an amount of at least 20% by weight relative to the total weight of the composition; said oily phase comprising at least one non-volatile non-phenyl silicone oil; and—a pulverulent phase in an amount of at least 40% by weight relative to the total weight of the composition; said pulverulent phase comprising at least mica particles; and—at least one amorphous hydrocarbon-based block copolymer; said composition not containing any talc particles that have not been surface-treated and being able to be obtained via a process comprising the following steps: (i) the oily phase, the amorphous hydrocarbon-based block copolymer, the pulverulent phase and the volatile solvent(s) are mixed to form a slurry; and (ii)